ProfileGDS5678 / 1425140_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 82% 80% 80% 83% 83% 80% 81% 84% 83% 79% 81% 80% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4652379
GSM967853U87-EV human glioblastoma xenograft - Control 25.9690482
GSM967854U87-EV human glioblastoma xenograft - Control 35.6028680
GSM967855U87-EV human glioblastoma xenograft - Control 45.8756880
GSM967856U87-EV human glioblastoma xenograft - Control 56.160883
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.858983
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5636380
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8267381
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1766584
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1292583
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5394679
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8150981
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6077280
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1088583